Emerging drugs for autonomic dysfunction in Parkinson's disease

Bibliography

• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease. Mov Disord 2010;25(Suppl 1):S94-7
   PubMedGoogle Scholar
• The National Institute for Clinical Excellence (NICE). Parkinson's disease diagnosis and management in primary and secondary care. Clinical Guide 35. The National Institute for Clinical Excellence (NICE), London;2006
   Google Scholar
• Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006;16:46-54
   PubMed Web of Science ®Google Scholar
• Senard JM, Rai S, Lapeyre-Mestre M, Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-9
   PubMed Web of Science ®Google Scholar
• Freeman R, Wieling W, Axelrod FB, Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011;161(1-2):46-8
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci 2010;289:74-80
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Clin Neurosci 1998;5:136-46
   PubMedGoogle Scholar
• Proulx M, de Courval FP, Wiseman MA, Salivary production in Parkinson's disease. Mov Disord 2005;20:204-7
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Taghva A, Shekarchi B, Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. Int J Impot Res 2010;22:325-35
   PubMed Web of Science ®Google Scholar
• Hobson P, Islam W, Roberts S, The risk of bladder and autonomic dysfunction in a community cohort of Parkinson's disease patients and normal controls. Parkinsonism Relat Disord 2003;10:67-71
   PubMed Web of Science ®Google Scholar
• Moore O, Gurevich T, Korczyn AD, Quality of sexual life in Parkinson's disease. Parkinsonism Relat Disord 2002;8:243-6
   PubMed Web of Science ®Google Scholar
• Hinnell C, Hurt CS, Landau S, Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson's disease? Mov Disord 2012;27:236-41
   PubMed Web of Science ®Google Scholar
• Feldstein C, Weder AB. Orthostatic hypotension: a common, serious and underrecognized problem in hospitalized patients. J Am Soc Hypertens 2012;6:27-39
   PubMed Web of Science ®Google Scholar
• Merello M. Sialorrhoea and drooling in patients with Parkinson's disease: epidemiology and management. Drugs Aging 2008;25:1007-19
   PubMed Web of Science ®Google Scholar
• Chou KL, Evatt M, Hinson V, Sialorrhea in Parkinson's disease: a review. Mov Disord 2007;22:2306-13
   PubMed Web of Science ®Google Scholar
• Bianchi J. Causes and strategies for moisture lesions. Nurs Times 2012;108:20-2
   PubMedGoogle Scholar
• Okereke CS. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson's disease patients experiencing motor fluctuations with levodopa. J Pharm Pharm Sci 2002;5:146-61
   PubMed Web of Science ®Google Scholar
• Ogawa E, Sakakibara R, Kishi M, Constipation triggered the malignant syndrome in Parkinson's disease. Neurol Sci 2012;33:347-50
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sullivan KL, Arnulf I, Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74:924-31
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26:S42-80
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, Factors related to orthostatic hypotension in Parkinson's disease. Parkinsonism Relat Disord 2012;18:501-5
   PubMed Web of Science ®Google Scholar
• Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005;30:173-8
   PubMed Web of Science ®Google Scholar
• Maule S, Papotti G, Naso D, Orthostatic hypotension: evaluation and treatment. Cardiovasc Hematol Disord Drug Targets 2007;7:63-70
   PubMedGoogle Scholar
• Thompson P, Wright J, Rajkumar C. Non-pharmacological treatments for orthostatic hypotension. Age Ageing 2011;40:292-3
   PubMed Web of Science ®Google Scholar
• Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing 2012;41:587-94
   PubMed Web of Science ®Google Scholar
• Lagalla G, Millevolte M, Capecci M, Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006;21:704-7
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004;62:37-40
   PubMed Web of Science ®Google Scholar
• Lagalla G, Millevolte M, Capecci M, Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol 2009;256(4):563-7
   PubMed Web of Science ®Google Scholar
• Arbouw ME, Movig KL, Koopmann M, Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010;74:1203-7
   PubMed Web of Science ®Google Scholar
• Bronner G. Practical strategies for the management of sexual problems in Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S96-100
   PubMedGoogle Scholar
• Bronner G. Sexual problems in Parkinson's disease: the multidimensional nature of the problem and of the intervention. J Neurol Sci 2011;310:139-43
   PubMed Web of Science ®Google Scholar
• Francis ME, Kusek JW, Nyberg LM, The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. J Urol 2007;178:591-6
   PubMed Web of Science ®Google Scholar
• Eardley I, Donatucci C, Corbin J, Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7:524-40
   PubMed Web of Science ®Google Scholar
• Shamliyan T, Wyman JF, Ramakrishnan R, Systematic review: benefits and harms of pharmacologic treatment for urinary incontinence in women. Ann Intern Med 2012;156(12):861-74
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Chancellor MB, Oguma K, Botulinum toxin type A for the treatment of lower urinary tract disorders. Int J Urol 2012;19:202-15
   PubMed Web of Science ®Google Scholar
• Ridout AE, Yoong W. Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy. J Obstet Gynaecol 2010;30:111-14
   PubMedGoogle Scholar
• Zeino Z, Sisson G, Bjarnason I. Adverse effects of drugs on small intestine and colon. Best Pract Res Clin Gastroenterol 2010;24:133-41
   PubMed Web of Science ®Google Scholar
• Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011;60:209-18
   PubMed Web of Science ®Google Scholar
• Pohl D, Tutuian R, Fried M. Pharmacologic treatment of constipation: what is new? Curr Opin Pharmacol 2008;8:724-8
   PubMed Web of Science ®Google Scholar
• Pare P, Bridges R, Champion MC, Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Can J Gastroenterol 2007;21(Suppl B):3B-22B
   PubMedGoogle Scholar
• Zangaglia R, Martignoni E, Glorioso M, Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007;22:1239-44
   PubMed Web of Science ®Google Scholar
• Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18:19-31
   PubMed Web of Science ®Google Scholar
• von Campenhausen S, Bornschein B, Wick R, Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005;15:473-90
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003;2:669-76
   PubMed Web of Science ®Google Scholar
• Bhavanani AB, Madanmohan Sanjay Z. Immediate effect of chandra nadi pranayama (left unilateral forced nostril breathing) on cardiovascular parameters in hypertensive patients. Int J Yoga 2012;5:108-11
   PubMedGoogle Scholar
• Lin G, Xiang Q, Fu X, Heart rate variability biofeedback decreases blood pressure in prehypertensive subjects by improving autonomic function and baroreflex. J Altern Complement Med 2012;18:143-52
   PubMed Web of Science ®Google Scholar
• Wang YP, Kuo TB, Lai CT, Effects of breathing frequency on baroreflex effectiveness index and spontaneous baroreflex sensitivity derived by sequence analysis. J Hypertens 2012;30:2151-8
   PubMed Web of Science ®Google Scholar
• Shahid IZ, Rahman AA, Pilowsky PM. Orexin A in rat rostral ventrolateral medulla is pressor, sympatho-excitatory, increases barosensitivity and attenuates the somato-sympathetic reflex. Br J Pharmacol 2012;165:2292-303
   PubMed Web of Science ®Google Scholar
• Krapalis AF, Reiter J, Machleidt F, Ghrelin modulates baroreflex-regulation of sympathetic vasomotor tone in healthy humans. Am J Physiol Regul Integr Comp Physiol 2012;302:R1305-12
   PubMed Web of Science ®Google Scholar
• Shang W, Han P, Yang CB, Synergism of irbesartan and amlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats. Acta Pharmacol Sin 2011;32:1109-15
   PubMed Web of Science ®Google Scholar
• Dogu O, Apaydin D, Sevim S, Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93-6
   PubMed Web of Science ®Google Scholar
• Tobin G, Giglio D, Lundgren O. Muscarinic receptor subtypes in the alimentary tract. J Physiol Pharmacol 2009;60:3-21
   PubMed Web of Science ®Google Scholar
• Proctor GB, Carpenter GH. Regulation of salivary gland function by autonomic nerves. Auton Neurosci 2007;133:3-18
   PubMed Web of Science ®Google Scholar
• El Sharkawi A, Ramig L, Logemann JA, Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry 2002;72:31-6
   PubMed Web of Science ®Google Scholar
• Meco G, Rubino A, Caravona N, Sexual dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2008;14:451-6
   PubMed Web of Science ®Google Scholar
• Giuliano F. Neurophysiology of erection and ejaculation. J Sex Med 2011;8(Suppl 4):310-15
   PubMed Web of Science ®Google Scholar
• Feifer A, Carrier S. Pharmacotherapy for erectile dysfunction. Expert Opin Investig Drugs 2008;17:679-90
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Uchiyama T, Yamanishi T, Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 2008;115:443-60
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Kishi M, Ogawa E, Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinsons Dis 2011;2011:924605
   PubMed Web of Science ®Google Scholar
• Jost WH. Gastrointestinal dysfunction in Parkinson's disease. J Neurol Sci 2010;289:69-73
   PubMed Web of Science ®Google Scholar
• Schoffer KL, Henderson RD, O'Maley K, Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22:1543-9
   PubMed Web of Science ®Google Scholar
• Kaufmann H. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 2008;18(Suppl 1):19-24
   PubMed Web of Science ®Google Scholar
• Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 2008;18(Suppl 1):25-9
   PubMed Web of Science ®Google Scholar
• Hauser RA, Gil R, Isaacson S. Efficacy of droxidopa in patients with PD. Available from: http://www movementdisorders org/congress/congress11/2011
   Google Scholar
• Hauser RA, Isaacson S. Impact of treatment with droxidopa in repeat fallers with Parkinson's disease and symptomatic neurogenic orthostatic hypotension (NOH 306A). Mov Disord 2012;27(Suppl 1):S423
   Google Scholar
• Savola JM, Hill M, Engstrom M, Fipamezole (JP-1730) is a potent alpha(2) adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003;18:872-83
   PubMed Web of Science ®Google Scholar
• Sorbera LA, Castaner J, Bayes M. Fipamezole hydrochloride. Antiparkinsonian, alpha(2)-adrenoceptor antagonist. Drugs Future 2003;28:14-17
   Web of Science ®Google Scholar
• Bara-Jimenez W, Chase TN. Hemodynamic effects of fipamezole in advanced Parkinson's disease. Neurology 2006;66:A214-15
   Web of Science ®Google Scholar
• Talakad S, Ganesan M, Gupta PK. Effect of partial weight supported treadmill gait training on cardiovascular dynamics in patients with Parkinson's disease. Mov Disord 2011;26(Suppl 1):S173
   PubMedGoogle Scholar
• Lloret SP, Nano G, Carrosella A, A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. J Neurol Sci 2011;310:248-50
   PubMed Web of Science ®Google Scholar
• Serrano-Dueñas M. Treatment of sialorrhea in Parkinson's disease patients with clonidine. Double-blind, comparative study with placebo. Neurologia 2003;18:2-6
   PubMed Web of Science ®Google Scholar
• Chnag CT, Chen P. A phase II, double-blind, randomized, placebo-controlled 4-way crossover study to evaluate the relative efficacy and safety of OC oral solution (oxybutynin and clonidine) for sialorrhoea in patients with Parkinson's disease. Mov Disord 2012;27(Suppl 1):S111
   Google Scholar
• Postma AG, Heesters M, van Laar T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov Disord 2007;22:2430-5
   PubMed Web of Science ®Google Scholar
• Thomsen TR, Galpern WR, Asante A, Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007;22:2268-73
   PubMed Web of Science ®Google Scholar
• Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002;17:1318-20
   PubMed Web of Science ®Google Scholar
• Hussain IF, Brady CM, Swinn MJ, Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-4
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Taghva A, Shekarchi B, Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. Int J Impot Res 2010;22:325-35
   PubMed Web of Science ®Google Scholar
• Pohanka M, Kanovsky P, Bares M, Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. Eur J Neurol 2004;11:483-8
   PubMed Web of Science ®Google Scholar
• Kulaksizoglu H, Parman Y. Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinson's disease. Parkinsonism Relat Disord 2010;16:531-4
   PubMed Web of Science ®Google Scholar
• Vaughan CP, Juncos JL, Burgio KL, Behavioral therapy to treat urinary incontinence in Parkinson disease. Neurology 2011;76:1631-4
   PubMed Web of Science ®Google Scholar
• Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24
   PubMedGoogle Scholar
• Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord 1995;10:337-40
   PubMed Web of Science ®Google Scholar
• Liu Z, Sakakibara R, Odaka T, Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005;20:680-6
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Giuliani M, Petty BG, Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects. Muscle Nerve 2000;23:189-92
   PubMed Web of Science ®Google Scholar
• Parkman HP, Rao SS, Reynolds JC, Neurotrophin-3 improves functional constipation. Am J Gastroenterol 2003;98:1338-47
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003;2:107-16
   PubMed Web of Science ®Google Scholar
• Ondo WG, Kenney C, Sullivan K, Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012;78:1650-4
   PubMed Web of Science ®Google Scholar
• Cassani E, Privitera G, Pezzoli G, Use of probiotics for the treatment of constipation in Parkinson's disease patients. Minerva Gastroenterol Dietol 2011;57:117-21
   PubMedGoogle Scholar
• Sullivan KL, Staffetti JF, Hauser RA, Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 2006;21:115-16
   PubMed Web of Science ®Google Scholar
• Grimes DA, Schulz KF. An overview of clinical research: the lay of the land. Lancet 2002;359:57-61
   PubMed Web of Science ®Google Scholar
• Jamnadas-Khoda J, Koshy S, Mathias CJ, Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory? Mov Disord 2009;24:1747-51
   PubMed Web of Science ®Google Scholar
• Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008;7:451-8
   PubMed Web of Science ®Google Scholar
• Pavy-Le TA, Amarenco G, Duerr S, The movement disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord 2011;26:1985-92
   PubMed Web of Science ®Google Scholar
• Mansourati J. Orthostatic hypotension: implications for the treatment of cardiovascular diseases. Presse Med 2012;41(11):1111-15
   PubMed Web of Science ®Google Scholar
• Lanier JB, Mote MB, Clay EC. Evaluation and management of orthostatic hypotension. Am Fam Physician 2011;84:527-36
   PubMed Web of Science ®Google Scholar
• Evatt ML, Chaudhuri KR, Chou KL, Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation–critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord 2009;24:635-46
   PubMed Web of Science ®Google Scholar
• Perez Lloret S, Piran AG, Rossi M, Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease. Mov Disord 2007;22:107-11
   PubMed Web of Science ®Google Scholar
• Samnieng P, Ueno M, Shinada K, Association of hyposalivation with oral function, nutrition and oral health in community-dwelling elderly Thai. Community Dent Health 2012;29:117-23
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Negre-Pages L, Ojero-Senard A, Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort. Eur J Neurol 2012;19:28-37
   PubMed Web of Science ®Google Scholar
• Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf 2004;27:1043-57
   PubMed Web of Science ®Google Scholar
• Rosen RC, Riley A, Wagner G, The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000;15:305-8
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Clinical investigation of medicinal products in the treatment of urinary incontinence. 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/11/WC500117971.pdf
   Google Scholar
• Winge K, Skau AM, Stimpel H, Prevalence of bladder dysfunction in Parkinson's disease. Neurourol Urodyn 2006;25:116-22
   PubMed Web of Science ®Google Scholar
• Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-45
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Whitehead WE, Chey WD, Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-51
   PubMed Web of Science ®Google Scholar